BR112012016767A2 - Método para diagnosticar se um paciente sofre de uma condição hepática ou do fígado, método para detectar o desenvolvimento de uma patologia do fígado, método para deter5 minar o risco de um paciente para uma condição do fígado e sistema para diagnosticar o estado de saúde hepática - Google Patents

Método para diagnosticar se um paciente sofre de uma condição hepática ou do fígado, método para detectar o desenvolvimento de uma patologia do fígado, método para deter5 minar o risco de um paciente para uma condição do fígado e sistema para diagnosticar o estado de saúde hepática

Info

Publication number
BR112012016767A2
BR112012016767A2 BR112012016767A BR112012016767A BR112012016767A2 BR 112012016767 A2 BR112012016767 A2 BR 112012016767A2 BR 112012016767 A BR112012016767 A BR 112012016767A BR 112012016767 A BR112012016767 A BR 112012016767A BR 112012016767 A2 BR112012016767 A2 BR 112012016767A2
Authority
BR
Brazil
Prior art keywords
liver
patient
condition
diagnosing
sufferes
Prior art date
Application number
BR112012016767A
Other languages
English (en)
Inventor
Houhou Leïla
Floch Jean-François
Original Assignee
Biorealites S A S
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorealites S A S, Servier Lab filed Critical Biorealites S A S
Publication of BR112012016767A2 publication Critical patent/BR112012016767A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

MÉTODO PARA DIAGNOSTICAR SE UM PACIENTE SOFRE DE UMA CONDIÇÃO HEPÁTICA OU DO FÍGADO, MÉTODO PARA DETECTAR O DESENVOLVIMENTO DE UMA PATOLOGIA DO FÍGADO, MÉTODO PARA DETERMINAR O RISCO DE UM PACIENTE PARA UMA CONDIÇÃO DO FÍGADO E SISTEMA PARA DIAGNOSTICAR O ESTADO DE SAÚDE HEPÁTICA. A presente invenção refere-se aos níveis de progastrina são determinados para diagnosticar uma ou mais patologias do fígado.
BR112012016767A 2010-01-08 2011-01-07 Método para diagnosticar se um paciente sofre de uma condição hepática ou do fígado, método para detectar o desenvolvimento de uma patologia do fígado, método para deter5 minar o risco de um paciente para uma condição do fígado e sistema para diagnosticar o estado de saúde hepática BR112012016767A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29355710P 2010-01-08 2010-01-08
PCT/EP2011/000047 WO2011083089A1 (en) 2010-01-08 2011-01-07 Progastrin and liver pathologies

Publications (1)

Publication Number Publication Date
BR112012016767A2 true BR112012016767A2 (pt) 2017-09-05

Family

ID=43567758

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012016767A BR112012016767A2 (pt) 2010-01-08 2011-01-07 Método para diagnosticar se um paciente sofre de uma condição hepática ou do fígado, método para detectar o desenvolvimento de uma patologia do fígado, método para deter5 minar o risco de um paciente para uma condição do fígado e sistema para diagnosticar o estado de saúde hepática

Country Status (15)

Country Link
US (1) US8900817B2 (pt)
EP (1) EP2542898B8 (pt)
JP (1) JP5543614B2 (pt)
KR (2) KR20120102157A (pt)
CN (1) CN102947707B (pt)
AU (1) AU2011204652B2 (pt)
BR (1) BR112012016767A2 (pt)
CA (1) CA2786437C (pt)
EA (1) EA023653B1 (pt)
ES (1) ES2636663T3 (pt)
NZ (1) NZ601593A (pt)
PL (1) PL2542898T3 (pt)
SG (1) SG182332A1 (pt)
WO (1) WO2011083089A1 (pt)
ZA (1) ZA201205002B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013002012A2 (pt) * 2010-07-26 2019-08-27 Centre Nat Rech Scient métodos e composições para terapia de câncer de fígado
FR2980196B1 (fr) * 2011-09-16 2013-10-04 Univ Dauvergne Clermont I Principe actif anticancereux issu de guiera senegalensis
WO2017114975A1 (en) 2015-12-31 2017-07-06 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating gastric cancer
KR102430893B1 (ko) 2015-12-31 2022-08-09 프로가스트린 에 캔서스 에스.에이 알.엘. 식도암을 검출 및 치료하기 위한 조성물 및 방법
WO2017114973A1 (en) * 2015-12-31 2017-07-06 Syncerus S.À R.L. Compositions and methods for assessing the risk of cancer occurrence
AU2017204682B2 (en) 2015-12-31 2021-07-29 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating ovarian cancer
EP3602061B1 (en) 2017-03-30 2022-07-20 ECS-Progastrin SA Compositions and methods for detecting lung cancer
CA3058263C (en) 2017-03-30 2023-08-01 Ecs-Progastrin Sa Compositions and methods for detecting prostate cancer
WO2019145537A1 (en) * 2018-01-26 2019-08-01 Ecs-Progastrin Sa Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
EP3759492A1 (en) * 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
RU2761729C1 (ru) * 2021-04-26 2021-12-13 Вячеслав Леонидович Коробка Способ оценки риска смерти при циррозе печени

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2384535C (en) 1991-03-04 2006-08-15 Bayer Corporation Automated analyzer
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6063026A (en) 1995-12-07 2000-05-16 Carbon Based Corporation Medical diagnostic analysis system
JP2002515458A (ja) * 1998-05-15 2002-05-28 アフトン・コーポレーシヨン 高ガストリン血症の予防および処置
US7668661B2 (en) * 2000-04-28 2010-02-23 Siemens Healthcare Diagnostics Inc. Liver disease-related methods and systems
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US7381370B2 (en) 2003-07-18 2008-06-03 Dade Behring Inc. Automated multi-detector analyzer
JP2008513536A (ja) * 2004-09-22 2008-05-01 レセプター バイオロジックス インコーポレイテッド プロガストリンに対するモノクローナル抗体
PL2040753T3 (pl) * 2006-05-22 2019-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitory progastryny w leczeniu raka okrężnicy
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
LT2488551T (lt) 2009-10-16 2018-10-25 Progastrine Et Cancers S.A R.L. Monokloniniai antikūnai prieš progastriną ir jų panaudojimas
BR112013002012A2 (pt) 2010-07-26 2019-08-27 Centre Nat Rech Scient métodos e composições para terapia de câncer de fígado

Also Published As

Publication number Publication date
EP2542898B8 (en) 2017-08-09
JP5543614B2 (ja) 2014-07-09
KR101688106B1 (ko) 2016-12-20
EP2542898B1 (en) 2017-05-03
SG182332A1 (en) 2012-08-30
US8900817B2 (en) 2014-12-02
KR20140132418A (ko) 2014-11-17
WO2011083089A1 (en) 2011-07-14
EA201200997A1 (ru) 2013-02-28
NZ601593A (en) 2014-08-29
PL2542898T3 (pl) 2017-10-31
AU2011204652A1 (en) 2012-07-26
CA2786437A1 (en) 2011-07-14
EP2542898A1 (en) 2013-01-09
ZA201205002B (en) 2013-10-30
KR20120102157A (ko) 2012-09-17
JP2013516617A (ja) 2013-05-13
EA023653B1 (ru) 2016-06-30
CN102947707A (zh) 2013-02-27
AU2011204652B2 (en) 2014-04-03
ES2636663T3 (es) 2017-10-06
US20110229488A1 (en) 2011-09-22
CN102947707B (zh) 2016-06-01
CA2786437C (en) 2020-09-01

Similar Documents

Publication Publication Date Title
BR112012016767A2 (pt) Método para diagnosticar se um paciente sofre de uma condição hepática ou do fígado, método para detectar o desenvolvimento de uma patologia do fígado, método para deter5 minar o risco de um paciente para uma condição do fígado e sistema para diagnosticar o estado de saúde hepática
MX364410B (es) Metodo para detectar nucleosomas que contienen nucleotidos.
MX349561B (es) Método para detectar nucleosomas que contienen variantes de histonas.
BR112013001752A2 (pt) método de detectar doenças ou condições usando células fagocídicas
EP3264090A3 (en) Method for detecting nucleosome adducts
MX368449B (es) Dispositivos, sistemas y metodos para detectar un diferencial bilateral en el umbral olfativo de olores puros.
BRPI0818801A2 (pt) Sistema de testes de diagnóstico.
NZ605698A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112014025189A2 (pt) prognóstico de eventos adversos em pacientes com suspeita de insuficiência cardíaca crônica
FR2942669B1 (fr) Methodes de segmentation d'images et de detection de structures particulieres.
BR112012021590A2 (pt) detecção de capacitância em ensaio eletroquímico
BR112014005130A2 (pt) método e sistema para recalibragem de sensor
BR112012010087A2 (pt) sistema adequado e método para monitorar o potencial de contaminação associado a um ou mais objetos dentro de um ambiente, dispositivo de monitoração adequado para monitorar e determinar o risco de contaminação associado a um objeto dentro de um ambiente, dispositivo indicador adequado para indicar a presença de fonte pontecial de contaminação ou de purificação dentro de um ambiente, e, kit de partes
WO2013023144A3 (en) Diagnostic biomarker profiles for the detection and diagnosis of parkinsons disease
WO2014036040A3 (en) Methods for diagnosis, prognosis and methods of treatment
WO2015070191A3 (en) Systems and methods for detection of genomic variants
WO2011143574A3 (en) Plasma biomarkers for diagnosis of alzheimer's disease
MX2016004167A (es) Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal.
FR2926639B1 (fr) Procede de traitement d'une image radar, issue en particulier d'un radar aeroporte, avec evaluation de l'altitude de l'isotherme 0°c
BRPI1009573A2 (pt) método para avaliar uma condição artrítica em um sujeito, kit para detectar a presença de um auto-anticorpo, e, método para determinar o subtipo de artrite em um paciente.
FR2954952B1 (fr) Procede de diagnostic fonctionnel d'un capteur de suie
WO2012158467A3 (en) Indicators for detecting the presence of metabolic by-products from microorganisms
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
WO2013009146A3 (ko) 당뇨망막병증 진단용 마커 및 이의 용도
WO2011158016A3 (en) Assay

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LES LABORATOIRES SERVIER (FR)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time
B350 Update of information on the portal [chapter 15.35 patent gazette]